Jincheng Pharm(SZ:300233)2022-12-07 08:16Group 1: Sales and Market Strategy - The company plans to continue using the existing sales model for Langyi, leveraging its brand and channel management advantages, with no significant competitors currently in the market [2][3] - Langyi's sales budget and targets for 2015 have been communicated to sales personnel, ensuring accountability [3] - The company is actively working on integrating Langyi's products into local medical insurance systems, with tender processes expected to resume after June due to policy changes [3] Group 2: Production and Development - The construction of Langyi's facilities is progressing as planned, with the formulation workshop nearing completion and raw material workshops still under construction, primarily funded through self-raised capital [3][4] - The acquisition of Langyi is expected to enhance the company's raw material production capabilities and quality control, thereby improving product quality and reducing production costs [3][4] Group 3: Product Portfolio and Market Position - Langyi's main products, such as Nitrofurantoin and Pidotimod, are positioned well in the market, with Nitrofurantoin being the only dual-category product (prescription + OTC) and holding the highest market share in 34 provinces [4] - Pidotimod is a leading immune regulator with a significant market share, and the company anticipates substantial revenue growth from this product over the next five years [4][5] Group 4: Future Opportunities and Challenges - The company is cautious about entering the health supplement market due to stringent approval processes but will consider products with competitive advantages [5] - There are no current plans to enter the medical device and service sectors [5] - The market for glutathione is expected to grow due to its wide range of applications, with potential demand increases in agriculture, health supplements, and food sectors [5]